文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

宫颈癌子宫切除术后切缘阳性患者辅助近距离放疗的生存获益

Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-06-08

基于美国国家癌症数据库2004至2015年1719例宫颈癌子宫切除术后切缘阳性并接受辅助放疗的患者,778例(45.3%)接受体外照射联合近距离放疗。中位随访3.8年,联合近距离放疗组3年总生存率为79.4%,单纯体外照射组为71.9%(log-rank P < .001)。多因素分析显示联合近距离放疗与生存显著改善相关(HR 0.77;95%CI 0.64-0.92;P = .003),倾向性评分匹配后生存获益持续存在(log-rank P = .005)。

要点

  • 宫颈癌子宫切除术后切缘阳性患者中,仅45.3%接受了辅助近距离放疗。
  • 联合近距离放疗组3年总生存率79.4%,单纯体外照射组71.9%(log-rank P < .001)。
  • 多因素分析HR 0.77(95%CI 0.64-0.92;P = .003),倾向性评分匹配后生存获益持续(log-rank P = .005)。

核心结论

  • 宫颈癌子宫切除术后切缘阳性患者中,体外照射联合近距离放疗较单纯体外照射显示显著改善的总生存。
  • 该队列中仅45.3%的患者接受了近距离放疗。

研究设计与样本

  • 利用美国国家癌症数据库识别2004至2015年诊断为宫颈癌、接受子宫切除术后辅助体外照射的患者,仅纳入切缘阳性者进行分析。
  • 共识别1719例患者,其中778例(45.3%)接受额外近距离放疗。
  • 采用逻辑回归评估近距离放疗使用的预测因素并进行倾向性评分匹配,采用log-rank检验和Cox比例风险模型在整体队列和倾向性评分匹配队列中比较生存。

主要发现

  • 中位随访3.8年,接受近距离放疗患者3年总生存率为79.4%,单纯体外照射患者为71.9%(log-rank P < .001)。
  • 多因素分析中,体外照射联合近距离放疗较单纯体外照射与显著改善的生存相关(HR 0.77;95%CI 0.64-0.92;P = .003)。
  • 倾向性评分匹配分析中,体外照射联合近距离放疗的生存获益持续存在(log-rank P = .005)。
  • 近距离放疗使用增加的预测因素包括年龄>55岁、私人保险而非政府保险、放疗疗程≥7周、体外照射剂量≥4500 cGy、放疗与手术间隔≤9周。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the use of brachytherapy (BT) in addition to external beam radiation therapy (EBRT) and the resulting effect on survival in patients with cervical cancer after hysterectomy with positive surgical margins. METHODS AND MATERIALS: Patients with cervical cancer diagnosed from 2004 to 2015 who underwent hysterectomy followed by adjuvant EBRT were identified using the National Cancer Database. Only patients with positive surgical margins were included for analysis. Logistic regression was used to evaluate predictors of BT use and for propensity score matching. Survival was compared between patients receiving EBRT alone and those receiving EBRT combined with BT for adjuvant treatment. Survival analysis using log-rank test and Cox proportional hazards modeling was performed in the overall and propensity score-matched cohorts. RESULTS: We identified 1719 patients who underwent hysterectomy with positive surgical margins followed by adjuvant radiation therapy, of whom 778 (45.3%) received additional BT. Predictors of increased receipt of BT included age >55 years, private rather than government insurance, radiation treatment duration ≥7 weeks, EBRT dose ≥4500 cGy, and time between radiation and surgery ≤9 weeks. With a median follow-up of 3.8 years, 3-year overall survival was 79.4% in patients receiving BT compared with 71.9% in patients receiving EBRT alone (log-rank P < .001). On multivariate analysis, EBRT and BT were associated with significantly improved survival (hazard ratio 0.77; 95% confidence interval 0.64-0.92; P = .003) compared with EBRT alone. The survival benefit of combining EBRT and BT persisted on propensity score-matched analysis (log-rank P = .005). CONCLUSIONS: In women with positive margins after hysterectomy for cervical cancer, the combination of EBRT and BT showed significantly improved overall survival compared with EBRT alone. However, only 45.3% of patients in our cohort received BT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Li R, Shinde A, Chen YJ, et al. Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29890264. doi:10.1016/j.ijrobp.2018.05.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。